BAYN.DE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:35):

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...

Stats
Dzisiejszy wolumen	2.58M
Średni wolumen	4.48M
Kapitalizacja rynkowa	27.53B
EPS	€0 ( 2024-03-04 )
Następna data zysków	( €2.32 ) 2024-05-14
Last Dividend	€2.40 ( 2023-05-02 )
Next Dividend	€0 ( N/A )
P/E	-9.40
ATR14	€0.0200 (0.07%)

Wolumen Korelacja

Długi: -0.06 (neutral)

Krótki: 0.00 (neutral)

Signal:(52.936) Neutral

Bayer AG Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bayer AG Korelacja - Waluta/Towar

0.91
( very strong )

0.77
( moderate )

0.00
( neutral )

0.86
( strong )

-0.69
( moderate negative )

Bayer AG Finanse

Annual	2023
Przychody:	€47.64B
Zysk brutto:	€27.89B (58.54 %)
EPS:	€-2.99

FY	2023
Przychody:	€47.64B
Zysk brutto:	€27.89B (58.54 %)
EPS:	€-2.99

FY	2022
Przychody:	€50.74B
Zysk brutto:	€30.87B (60.84 %)
EPS:	€4.22

FY	2021
Przychody:	€44.08B
Zysk brutto:	€27.27B (61.85 %)
EPS:	€1.018

Financial Reports:

No articles found.

Bayer AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€2.40 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Bayer AG Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.23 - low (7.68%) | Divividend Growth Potential Score: 1.218 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€1.279	2000-05-02
Last Dividend	€2.40	2023-05-02
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	25	--
Total Paid Out	€43.29	--
Avg. Dividend % Per Year	0.00%	--
Score	1.42	--
Div. Sustainability Score	3.23
Div.Growth Potential Score	1.218
Div. Directional Score	2.23	--

Next Divdend (Est)
(2025-03-31)

€2.45 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.42

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
PRG.DE	Ex Dividend Knight	2023-07-20	Quarterly	0.00%
AMG.DE	Ex Dividend Knight	2023-08-17	Quarterly	0.00%
HHFA.DE	Ex Dividend Junior	2023-06-16	Annually	0.00%
SNW.DE	Ex Dividend Junior	2023-05-30	Annually	0.00%
BZ7A.F	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
KRN.DE	Ex Dividend Knight	2023-05-24	Annually	0.00%
UWS.DE	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
DKG.DE	No Dividend Player	2023-07-14	Annually	0.00%
NF4.DE	No Dividend Player	2023-06-27	Sporadic	0.00%
4AB.DE	Ex Dividend Knight	2023-10-12	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0617	1.500	-1.235	-1.852	[0 - 0.5]
returnOnAssetsTTM	-0.0238	1.200	-0.795	-0.954	[0 - 0.3]
returnOnEquityTTM	-0.0816	1.500	-2.02	-3.03	[0.1 - 1]
payoutRatioTTM	-0.809	-1.000	-8.09	8.09	[0 - 1]
currentRatioTTM	1.259	0.800	8.70	6.96	[1 - 3]
quickRatioTTM	0.784	0.800	-0.0946	-0.0757	[0.8 - 2.5]
cashRatioTTM	0.201	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.355	-1.500	4.08	-6.11	[0 - 0.6]
interestCoverageTTM	0.595	1.000	-0.891	-0.891	[3 - 30]
operatingCashFlowPerShareTTM	4.85	2.00	8.38	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.05	2.00	8.97	10.00	[0 - 20]
debtEquityRatioTTM	1.332	-1.500	4.67	-7.01	[0 - 2.5]
grossProfitMarginTTM	0.585	1.000	3.58	3.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.0333	1.000	-1.333	-1.333	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.109	1.000	-0.507	-0.507	[0.2 - 2]
assetTurnoverTTM	0.386	0.800	-0.759	-0.607	[0.5 - 2]
Total Score				3.23

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-9.36	1.000	-1.046	0	[1 - 100]
returnOnEquityTTM	-0.0816	2.50	-1.297	-3.03	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.05	2.00	9.32	10.00	[0 - 30]
dividendYielPercentageTTM	0.393	1.500	0.186	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.85	2.00	8.38	10.00	[0 - 30]
payoutRatioTTM	-0.809	1.500	-8.09	8.09	[0 - 1]
pegRatioTTM	0.120	1.500	-2.54	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.100	1.000	10.00	0	[0.1 - 0.5]
Total Score				1.218

Bayer AG

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.